Skip to main content

Steroids

ICYMI: EULAR guidelines rec starting prednisone dose in #PMR to be between 12.5-25mg/d. A cross sectional study of 138 pts (63M, 75F, age 73.4 yes) saw the mean starting dose to be 19.2±7.7 mg.  https://t.co/Yf3yqRRMCK

Dr. John Cush @RheumNow( View Tweet )

Jul 29, 2021
Steroid (GC) withdrawal studied in T2T RA cohort of 207 RA pts (F/U 39 mos); Only 60% discontinued GC, w/ low risk of flare. BUT D/Cs were SLOW w/ only 9.7%, 26.6%, 48.0% & 58.6% at 6 mos, 1, 2 & 3 yrs - median time to cessation = 27 mos https://t.co/h02aueYKwN

Dr. John Cush @RheumNow( View Tweet )

Jul 23, 2021

Fracture Risk with Low Dose Steroid

Jul 22, 2021

A large RA cohort analysis shows that low-dose glucocorticoid therapy in rheumatoid arthritis (RA) patients may carry an increased risk of vertebral osteoporotic (OP) fractures. 



There were 15,123 RA patients (mean age 68.8 years) enrolled in Clinical Practice Research Datalink

Read Article
EULAR guidelines rec starting prednisone dose in #PMR to be between 12.5-25mg/d. A cross sectional study of 138 pts (63M, 75F, age 73.4 yes) saw the mean starting dose to be 19.2±7.7 mg.  https://t.co/Yf3yqRRMCK

Dr. John Cush @RheumNow( View Tweet )

Jul 21, 2021

FDA Approves IVIG in Dermatomyositis

Jul 20, 2021

The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).



The manufacturer, Octapharma USA, received

Read Article

ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis and Takayasu Arteritis

Jul 19, 2021

The ACR and the Vasculitis Foundation have published their evidence-based recommendations and expert guidance for the management of GCA and Takayasu arteritis. These recommendations address a variety of clinical questions and scenarios including diagnostic testing, imaging, treatments, and

Read Article

Osteonecrosis in Lupus

Jul 15, 2021

A single center analysis of systemic lupus erythematosus (SLE) patients found symptomatic osteonecrosis (ON) in nearly 10%.



Researchers analyzed data from 912 SLE patients admitted to the hospital (1981 to 2012).  Of these 912 SLE patients, 97 had symptomatic ON with an overall

Read Article

Slow Steroid Tapering Succeeds in SLE

MedPage Today
Jul 13, 2021

Gradual withdrawal of glucocorticoids was successful among patients with systemic lupus erythematosus (SLE) after 2 years of clinically quiescent disease, without an increased likelihood of flares, Canadian researchers reported.



At 12 months, the flare rate among patients who had

Read Article
Metanalysis of 33 clinical trials show that corticosteroids are anaglesic, especially in 1st 3 mos (mean drop VAS pain -12mm); after that benefit wanes to -8mm @3-6 mos and -6mm (95% CI, -10mm, -2mm) after  6 mos. https://t.co/IKZhqqwhPO

Dr. John Cush @RheumNow( View Tweet )

Jul 12, 2021

ICYMI: RheumNow Podcast – Tofacitinib Safety Concerns

Jul 09, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article

ICYMI: EULAR Guidelines on Intraarticular Therapy

Jul 07, 2021

EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.



The

Read Article

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article

How Do You Measure Success When It Comes to SLE?

Jun 10, 2021

EULAR 2021 opened with a grand debate to answer this essential question:  should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?  

Read Article

RA after 70: Too Old for bioDMARDs?

In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.



Importantly, treating people living with RMDs above the age of 70 -

Read Article
#EULAR2021 POS0105: Predictors of flare in SLE low disease activity state: ⭐️Ongoing glucocorticoid treatment ⭐️Ongoing immunosuppressant treatment ⭐️Anti-RNP antibody @RheumNow

Eric Dein @ejdein1( View Tweet )

Jun 05, 2021
Rheum alliance trainee survey (n=302): 87-96% report negative impact of COVID19 on Rheumatology training: -outpatient clinics (79%) -inpatient consultations (59%) -formal teaching (55%) -procedures (53%) and -ultrasonography (36%) #POS0051 @RheumNow #EULAR2021 @kristenyoung

Aurelie Najm @AurelieRheumo( View Tweet )

Jun 03, 2021
Very informative #EULAR2021 WIN session on MIS-C @EULAR_org 👉 Steroids early 👉 IVIg in all 👉 anticoagulant use remains variable #Coronary aneurysms ✅ occur during acute phase in MIS-C and improve with treatment ✅ occur in the late/convalescent phase of #Kawasaki disease https://t.co/Ff3rX6u5VK
Ashima Makol MD @AshimaMakol( View Tweet )
Jun 03, 2021
Which drug are you most excited about changing future treatments in SLE? #EULAR2021 @RheumNow

Eric Dein @ejdein1( View Tweet )

Jun 03, 2021
Based on the data, what would you do in a new SLE patient w/LN class IV who is already on a background of GC's+HCQ? @rheumnow @kidneydoc101 @Lupusreference
Jun 03, 2021
Our meta-analysis on IA GC effects on pain and function in knee OA vs. controls at different time points: short term superiority of IA GC, medium term effect is no longer significant apart vs PBO and long term IA GC non superior vs controls. #EULAR2021 @RheumNow #POS1099 https://t.co/mQ0bMF03IT
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 02, 2021
Can we taper IV belimumab in #SLE? Dr Fredi reported 14/48 (29%) extended tx to at least 5-weekly after 12mo of tx. No worsening C3/C4 & PGA but interestingly #steroid and SLEDAI ⬇️. More works needed to identify suitable pts for taper and regime #EULAR2021 #POS0107 @RheumNow https://t.co/Gwe7mPWPdY
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 02, 2021
In patients with #SLE who attained LLDAS, a retrospective cohort study by Dr Cunha identified predictors of flares including anti-RNP +ve, concomitant immunosuppressant and oral prednisolone. Important to account these during follow-up #EULAR2021 #POS0105 @RheumNow

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Jun 02, 2021
🚨So after LoVAS Now this Ritux + MMF + Pulse MPS No oral steroids 🤯 @ARD_BMJ @EBRheum - Lesser is better ?? https://t.co/CYMNX8wLtd https://t.co/NtwTas3ZdS
EnvisionRheumat @ERheumat( View Tweet )
Jun 02, 2021
Dr. Tani: Who has trouble tapering below 5mg/d prednisone in SLE ☑️Older patients ☑️High disease activity ☑️Skin and MSK manifestations ☑️Pts treated before 2000. Try to avoid long-term steroid usage early in the disease course, as it gets harder over time. #EULAR2021, @RheumNow

Eric Dein @ejdein1( View Tweet )

Jun 02, 2021
I'm presenting data on COVID-19 in Irish rheumatic disease patients. Age, number comorbidities, glucocorticoids, associated increased hospitalisation. Inflammatory arthritis associated decreased hospitalisation. @RheumNow #EULAR2021 #AbstrPOS1162 https://t.co/0gKxiMNYTf
Richard Conway @RichardPAConway( View Tweet )
Jun 02, 2021
×